Lupin buys diabetes brands Ondero, Ondero Met from Boehringer Ingelheim International for Rs 235 Crore

Published On 2023-08-19 08:57 GMT   |   Update On 2023-08-19 08:57 GMT
Advertisement

Mumbai: Global pharma major Lupin Limited has announced the acquisition of diabetes brands ONDERO and ONDERO MET, from Boehringer Ingelheim International GmbH, including the trademark rights associated with these brands. The cost of acquisition of brands is Euro 26 million.

Lupin has been marketing ONDERO and ONDERO MET since 2015 in the Indian market as part of a comarketing agreement with Boehringer Ingelheim India.

Advertisement

In India, an estimated 77 million people above the age of 18 years have Type-2 Diabetes, while nearly 25 million are pre-diabetic, at higher risk of developing diabetes in the future.

“Lupin is at the forefront of providing quality pharmaceutical products to patients. With the acquisition of ONDERO and ONDERO MET, we continue to offer a wide portfolio of products to enable access to medication for patients, and further consolidate our position as a market leader in the anti-diabetes segment,” said Nilesh Gupta, Managing Director, Lupin.

Commenting on the acquisition, Rajeev Sibal, President – India Region Formulations, Lupin said, “The disease burden of diabetes is constantly increasing fueled by the prevalence of obesity and unhealthy lifestyles. This important acquisition reflects our steadfast dedication in empowering healthcare professionals to combat the growing menace of diabetes in India and significantly improve the lives of those facing this challenging disease.”

Read also: Lupin rolls out Tiotropium Bromide Inhalation Powder for COPD in US

Lupin is an innovation-led transnational pharmaceutical company headquartered in Mumbai, India. The Company develops and commercializes a wide range of branded and generic formulations, biotechnology products, and APIs in over 100 markets in the U.S., India, South Africa, and across the Asia Pacific (APAC), Latin America (LATAM), Europe, and Middle East regions. The Company specializes in the cardiovascular, anti-diabetic, and respiratory segments and has a significant presence in the anti-infective, gastro-intestinal (GI), central nervous system (CNS), and women’s health areas. Lupin invested 7.9% of its revenue in research and development in FY23. 
Tags:    

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News